Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 943 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Cardiac Toxicity, Sarcoma
Interventions
filgrastim, cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, methotrexate, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
4
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Conditions
Leukemia
Interventions
filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Leukemia
Interventions
filgrastim, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
Lung Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
76
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Concord, California + 64 more
Conditions
Leukemia
Interventions
filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Conditions
Leukemia
Interventions
filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 69 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Paterson, New Jersey
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, carboplatin, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, dexamethasone, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Non-Hodgkin's Lymphoma
Interventions
Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • Aurora, Colorado
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more